Moderna (MRNA) Stock

Moderna's recent difficulties have made it an attractive option for acquisition. Merck is in urgent need of Moderna's mRNA-based Personal Cancer Vaccines (PCVs) to prolong the patent protection of KEYTRUDA past 2028. With a potential loss of $62 billion over four years after KEYTRUDA's exclusivity ends, Moderna's $13 billion market value seems like a good deal.

In 2024, Moderna's share prices dropped by 58%, making it one of the poorest performers in the S&P 500 index. The biotech company, known for its innovative mRNA vaccines, has faced challenges with low sales of its COVID-19 vaccine and slow acceptance of its new vaccine for respiratory syncytial virus (RSV).

Jared Holz, a strategist for Mizuho in the healthcare sector, appears on 'Closing Bell Overtime' to discuss Moderna and Novo Nordisk.

The company stated that the package will offer extra help for the final stages of development and approval of mRNA-based vaccines that were created before the pandemic.

On January 17, 2025, Moderna, Inc. (NASDAQ:MRNA) revealed that it is receiving continued support from the U.S. Department of Health and Human Services (HHS) to speed up the creation of mRNA-based vaccines for pandemic influenza. This funding comes through the Rapid Response Partnership Vehicle (RRPV) Consortium, which is backed by the Biomedical Advanced Research and Development Authority (BARDA), a part of HHS's Administration for Strategic Preparedness and Response (ASPR).

The U.S. government has given Moderna $590 million to help with the final stages of developing its mRNA vaccine for bird flu, as the country intensifies its efforts to address the rising number of infections in people.

This Analyst Blog features Moderna, Regeneron, Intellia Sage, and GSK.

Due to the uncertainty about its overall growth, we recommend that short-term investors avoid MRNA stock.

Even though the stock market has been performing well this week, vaccine technology firm Moderna (MRNA -2.72%) is not sharing in that success. The company, known for creating one of the first COVID-19 vaccines, has seen its stock drop by 20% by Thursday afternoon.